S U M M A R Y Mutations in FAM20C were recently identified as the cause of lethal osteosclerotic bone dysplasia, which highlighted the important role of this molecule in biomineralization. No systematic studies have been performed to evaluate the expression pattern of this relatively new molecule in the developmental processes of bone and tooth. In the present study, we analyzed in detail the expression profile of FAM20C during osteogenesis and odontogenesis using ISH and IHC approaches. The specimens analyzed were mouse tissues spanning embryonic day 13.5 (E13.5) to postnatal 8 weeks. The earliest presence of FAM20C was observed at E14.5. During osteogenesis, FAM20C mRNA was detected in the chondrocytes and osteoblasts of the long bone, whereas its protein was observed in the extracellular matrix (ECM) of bone and in the cytoplasm of the chondrocytes, osteoblasts, and osteocytes. During odontogenesis, FAM20C mRNA was detected in the ameloblasts, odontoblasts, cementoblasts, and periodontal ligament fibroblasts, whereas its protein was observed in the matrices of dentin, enamel, and alveolar bone and in the cytoplasm of the aforementioned cells. The temporospatial expression profile revealed in this study indicates that FAM20C is an ECM protein that may play an important role in controlling the mineralization of bone and tooth. (J Histochem Cytochem 58:957-967, 2010) 
S U M M A R Y Mutations in FAM20C were recently identified as the cause of lethal osteosclerotic bone dysplasia, which highlighted the important role of this molecule in biomineralization. No systematic studies have been performed to evaluate the expression pattern of this relatively new molecule in the developmental processes of bone and tooth. In the present study, we analyzed in detail the expression profile of FAM20C during osteogenesis and odontogenesis using ISH and IHC approaches. The specimens analyzed were mouse tissues spanning embryonic day 13.5 (E13.5) to postnatal 8 weeks. The earliest presence of FAM20C was observed at E14.5. During osteogenesis, FAM20C mRNA was detected in the chondrocytes and osteoblasts of the long bone, whereas its protein was observed in the extracellular matrix (ECM) of bone and in the cytoplasm of the chondrocytes, osteoblasts, and osteocytes. During odontogenesis, FAM20C mRNA was detected in the ameloblasts, odontoblasts, cementoblasts, and periodontal ligament fibroblasts, whereas its protein was observed in the matrices of dentin, enamel, and alveolar bone and in the cytoplasm of the aforementioned cells. The temporospatial expression profile revealed in this study indicates that FAM20C is an ECM protein that may play an important role in controlling the mineralization of bone and tooth. (J Histochem Cytochem 58:957-967, 2010) K E Y W O R D S family with sequence similarity 20 C dentin matrix protein 4 osteogenesis odontogenesis lethal osteosclerotic bone dysplasia LETHAL AND NON-LETHAL OSTEOSCLEROTIC bone dysplasias are autosomal recessive hereditary diseases. Individuals affected by these congenital disorders show a generalized increase in bone density and a marked increase in the ossification of the skull and facial bones, along with extensive intracranial calcification (Raine et al. 1989) .
Recently, mutations in the FAM20C gene were found to be associated with these diseases, which highlighted the critical role of this molecule in the development and mineralization of the skeleton (Simpson et al. 2007 (Simpson et al. , 2009 . FAM20C, also known as dentin matrix protein 4 , is a member of the evolutionarily conserved FAM20 family of proteins; the sequence for this group of proteins is similar to that of FAM20A, which was identified through its expression during hemato-poietic differentiation. Sequence analysis revealed that the FAM20C protein contains a putative signal sequence at its N-terminus and a highly conserved region of ?350 amino acids near its C-terminus [referred to as the conserved C-terminal domain (CCD) (Nalbant et al. 2005) . Except for the CCD, no other potential functional domains have been detected by several annotation search software programs. RT-PCR revealed that FAM20C was expressed in a wide variety of tissues (Nalbant et al. 2005) . The results of ISH performed on sections from 3-day-old mouse heads showed the expression of FAM20C in differentiated odontoblasts, ameloblasts, and osteoblasts ). Although the above two studies provided preliminary data regarding the expression of FAM20C in different tissues, there is a need to systematically evaluate the temporospatial expression and distribution of this molecule in the skeleton and tooth at various stages of development.
In the present study, we analyzed the expression and distribution of FAM20C in the mouse bone and tooth by using the ISH and IHC techniques. The profile of the FAM20C expression during the development of the skeletal and dental tissues demonstrated by this study provides novel clues about the biological functions of this molecule in osteogenesis and odontogenesis.
Materials and Methods

Sample Preparation
Preliminary studies in our laboratory revealed that FAM20C was first detectable in the osseous tissues of CD-1 mice at embryonic day 14.5 (E14.5), and its expression in the bone and teeth began to fade away after postnatal 7 weeks. In this report, we describe the findings obtained from analyses of CD-1 mice (Harlan Laboratory; Houston, TX) at the developmental stages of E13.5, E14.5, E15.5, E16.5, newborn, and 1, 3, 5, 7, and 8 weeks after birth. These mice were used to systematically analyze the expression of FAM20C in the skeleton and tooth. The whole embryos at the stages of E13.5, E14.5, and E15.5 were processed for ISH and IHC analyses; the femurs and heads of the E16.5, newborn, and 1-week-old mice were dissected for specimen preparation, and the femurs and mandibles of the 3-, 5-, 7-, and 8-week-old mice were dissected and processed for the same analyses.
The acquired tissues were fixed with 4% paraformaldehyde in PBS solution at 4C overnight. The femurs and mandibles from the 1-, 3-, 5-, 7-, and 8-week-old mice were decalcified in 15% EDTA (pH 7.4) at 4C for 2, 4, 6, 8, and 9 days, respectively. The PBS and EDTA solutions were prepared using water pretreated with 0.1% diethylpyrocarbonate. The tissues were processed for paraffin embedding, and serial 5-mm sections were prepared. The animal protocol was approved by the Baylor College of Dentistry Institutional Animal Use and Care Committee, Texas A&M Health Science Center (Dallas, TX).
In Situ Hybridization
With the full-length mouse FAM20C cDNA ) as a template, a 900-bp fragment was obtained by PCR amplification using forward primer 5′-GCGGCCATGAAGATGATACT-3′ and reverse primer 5′-CTCCTGCTCTCTCGTCTGCT-3′. The PCR product was then subcloned into the pCRII-TOPO vector (Invitrogen; Carlsbad, CA), which was linearized with HindIII to synthesize the antisense RNA probes using the T7 RNA polymerase or with XhoI to synthesize the sense RNA probes using the Sp6 RNA polymerase. The probes were labeled with digoxigenin (DIG) using an RNA Labeling Kit (Roche; Indianapolis, IN). DIGlabeled RNA probes were detected by an enzyme-linked immunoassay using a specific anti-DIG-alkaline phosphatase antibody conjugate (Roche) and an improved substrate, which produces a red color for positive signals (Vector Laboratories; Burlingame, CA), according to the manufacturer's instructions. The sense probe was used in place of the antisense probe in the negative control experiments. A detailed description of the protocols of ISH and methyl green counterstaining can be found in our previous reports (Feng et al. 2002; Baba et al. 2004) .
Immunohistochemistry
To generate polyclonal antibodies against FAM20C, we designed three oligopeptides: one from the N-terminal region and the others from the C-terminal region of the mouse FAM20C. These three oligopeptides were used to immunize rabbits to obtain polyclonal antibodies (YenZym Antibodies; South San Francisco, CA). Among the three anti-FAM20C polyclonal antibodies, the one generated using the oligopeptide CSSVVEDDLATEH-RASTER from the C-terminal region of mouse FAM20C demonstrated a high titer and appropriate specificity and was used for the IHC and Western immunoblotting in this study. This rabbit antiserum was purified by an affinity column made of the oligopeptide CSSVVEDDLATEH-RASTER. The titer of the affinity-purified antibody, revealed by ELISA using the immunizing oligopeptide as the antigen, was 1:50,000 (8 ng/ml). The specificity of this polyclonal antibody was confirmed by carefully designed control IHC experiments and Western immunoblotting (described later).
The IHC experiments were carried out using an ABC kit and a DAB kit (Vector Laboratories), according to the manufacturer's instructions. The anti-FAM20C antibody was used at a concentration of 1 mg IgG/ml. Two sets of control experiments were performed to confirm the specificity of the affinity-purified anti-FAM20C antibody. In the first set, rabbit IgG (Abcam; Cambridge, MA) at a concentration of 1 mg IgG/ml was used to replace the anti-FAM20C antibody in the IHC experiments. In the second set of control experiments, the anti-FAM20C antibody solution (1 mg IgG/ml) was preincubated overnight with the immunizing oligopeptide at an antibody/ oligopeptide ratio of 1:50 before it was applied to the sections. In the IHC experiments, methyl green was used for counterstaining.
von Kossa Staining
To examine if FAM20C localizations overlap with the mineralization areas, we performed von Kossa staining on E14.5 mouse head sections serial to those used for the IHC of FAM20C. For von Kossa staining, the paraffin sections of E14.5 mouse head (undecalcified) were deparaffinized and hydrated with water. After being rinsed in several changes of distilled water, the sections were incubated with 1% silver nitrate solution under a 60-W light bulb for 2 hr. The sections were then rinsed in several changes of distilled water and incubated in 5% sodium thiosulfate for 5 min to remove the unreacted silver. Finally, the specimens were counterstained with nuclear fast red for 5 min.
Generation of Recombinant FAM20C and Western Immunoblotting
The coding sequence of mouse FAM20C cDNA was subcloned into the bicistronic pMES vector (Swartz et al. 2001 ) in front of the internal ribosome entry siteenhanced green fluorescent protein sequence and downstream to a chicken b-actin promoter. A STOP cassette flanked by LoxP sequences was inserted between the b-actin promoter and the FAM20C sequence. This conditional transgenic construct was named "pMES-STOP-FAM20C." To generate recombinant FAM20C, the pMES-STOP-FAM20C construct and PBS185 vector (plasmid 11916; Addgene, Cambridge, MA) (Sauer and Henderson 1990) were co-transfected into human embryonic kidney 293-Epstein-Barr virus nuclear antigen (HEK293-EBNA) cells. The Cre recombinase expressed by the PBS185 vector removed the floxed STOP cassette in pMES-STOP-FAM20C and thus initiated the transcription of FAM20C in the cells. Samples from non-transfected cells or cells transfected with only the pMES-STOP-FAM20C construct were used as negative controls. After transfection, the cells were cultured in conditional (serum-free) DMEM for 48 hr before both cells and medium were collected for analysis. The cell extract (lysate) and an equal portion of culture medium were loaded onto 12% SDS-PAGE for Western immunoblotting analyses. The FAM20C polyclonal antibody was used at a concentration of 400 ng/ml in the Western immunoblotting experiments. An anti-b-actin monoclonal antibody (clone AC-15; Sigma, St Louis, MO) was used at a concentration of 0.5 mg/ml to detect the mouse b-actin, which served as an internal control for this experiment.
Results
Specificity of the Anti-FAM20C Antibody and Detection of Recombinant FAM20C
To test the specificity of the anti-FAM20C antibody and to examine if FAM20C is a secretory protein, we performed Western immunoblotting with this antibody on the cell lysates and culture medium from HEK293-EBNA cells co-transfected with the pMES-STOP-FAM20C and the PBS185 constructs.
In the Western immunoblotting analyses, a protein band migrating at ?63 kDa (just below the 75-kDa molecular mass marker) was recognized by the anti-FAM20C antibody (Figure 1 ). This protein band was present in the cell lysates and in the culture medium from the cells co-transfected with the pMES-STOP-FAM20C and the PBS185 constructs, but was completely absent in the samples from the non-transfected cells or cells transfected with only the pMES-STOP-FAM20C construct. It is worth noting that the protein band from the culture medium had a remarkably greater intensity compared with the cell lysates, indicating that the majority of the FAM20C protein was secreted into the culture medium. The results of these experiments have not only confirmed the specificity of the anti-FAM20C antibody but also provided clear evidence that FAM20C is a secretory protein.
FAM20C Expression in Bone
Neither FAM20C mRNA nor its protein was detected in any chondrogenic or osteogenic tissues at E13.5 (data not shown). At E14.5, FAM20C was undetectable in Figure 1 Western immunoblotting to detect FAM20C in the cell lysates and culture medium from human embryonic kidney 293-Epstein-Barr virus nuclear antigen (HEK293-EBNA) cells. Cell lysates and the culture media from the transfected or non-transfected cells were loaded onto 12% SDS-PAGE gels and then probed with the anti-FAM20C polyclonal antibody. b-Actin was used as an internal control. Lane 1: Cell lysates from HEK293-EBNA cells not transfected with any DNA constructs. The sample was 1/50 of the total cell lysates (in radioimmunoprecipitation assay buffer containing b-mercaptoethanol) collected from a 2-ml culture well. Lane 2: Cell lysates from HEK293-EBNA cells transfected with the pMES-STOP-FAM20C, but not with PBS185 construct. The sample was 1/50 of the total cell lysates collected from a 2-ml culture well. Lane 3: Cell lysates from HEK293-EBNA cells co-transfected with the pMES-STOP-FAM20C and PBS185 constructs. The sample was 1/50 of the total cell lysates collected from a 2-ml culture well. Note that the ?63-kDa protein band ( just below the 75-kDa molecular mass marker) was recognized by the anti-FAM20C antibody. Because this ?63-kDa protein band was not observed in the Lane 1 and Lane 2 samples, it must be FAM20C. Lane 4: Culture medium from HEK293-EBNA cells co-transfected with the pMES-STOP-FAM20C and PBS185 constructs. The sample was 1/50 of the total medium collected (b-mercaptoethanol added) from a 2-ml culture well. The ?63-kDa protein band recognized by the anti-FAM20C antibody was remarkably stronger than that in the sample from the cell lysates. This observation indicates that the majority of FAM20C was secreted into the medium. any long bones by either ISH or IHC; however, both FAM20C mRNA and protein were detected in the osteoblasts at the ossification sites of the craniofacial membrane bones (see later).
The mouse femur at E15.5 was used to illustrate the expression of FAM20C in the osseous and cartilaginous tissues. In the E15.5 embryo femur, FAM20C mRNA and protein were observed in the osteoblasts and cells that appeared to be osteoprogenitors, whereas the protein was also detected in the extracellular matrix (ECM) in the primary ossification center (POC) (Figures 2A-2D ). The expression level of FAM20C at E16.5 relatively increased and was observed in broader areas in the osseous tissues ( Figures 2E-2H ) compared with its distribution at E15.5.
In the newborn (Figures 2I-2L ) and 1-week-old mice ( Figures 3A-3D ), the expression of FAM20C could not be detected in the POC, but was found in the osteoblasts and newly formed osteocytes along or within the osteoid matrix of the trabecular bone and cortical bone. The expression of FAM20C in the femur reached its maximal level at 3 weeks after birth (Figures 3E and 3H) . At this stage, both the mRNA and protein for FAM20C were abundant in the articular chondrocytes, proliferative chondrocytes, and prehypertrophic and hypertrophic chondrocytes (Figures 3F and 3I ) and in the osteoblasts lining the trabecular bone and osteoid ( Figures 3G and 3J) . FAM20C protein was also detected in the mature osteocytes and in the ECM of the femur.
At 7 weeks after birth, FAM20C mRNA and its protein were observed in the osteoblasts lining the trabecular bone in the femur (Figures 3M and 3P) , but the expression level of FAM20C was dramatically reduced ( Figures 3K  and 3N ), when compared with earlier time points. At this stage, FAM20C mRNAwas undetectable in the articular chondrocytes and mature osteocytes of the femur (Figure 3L ), whereas its protein was observed in these cells and in the ECM of the bone ( Figure 3O ).
FAM20C Expression in the Teeth
In this study, we systematically evaluated the expression of FAM20C in the molars and incisors of the mouse mandible. For reporting purposes, the results from the first lower molar and lower incisor, along with their surrounding periodontal ligament (PDL), were used to illustrate the expression of FAM20C during odontogenesis.
Neither FAM20C mRNA nor its protein was detected in any tissues of the mandible at E13.5 (data not shown). At E14.5, both FAM20C mRNA and protein were detected in the osteoblasts at the ossification sites of the craniofacial membrane bones. In addition, the localizations of FAM20C in these craniofacial bones overlapped with the mineralization areas as clarified by von Kossa staining ( Figures 4A and 4B) . When the first lower molar reached its early cap stage at E14.5, FAM20C mRNA and its protein were observed in the dental epithelium of the enamel organ ( Figures 4C, 4D , 4F, and 4G) and in the osteoblasts of the alveolar bone ( Figures 4E and  4H ). FAM20C protein was also observed in the ECM of the alveolar bone osteoid, although the signals for the protein appeared diffused in these epithelial cells. At E15.5 (late cap stage) and E16.5 (bell stage), the FAM20C was seen in the ameloblast layer and the prospective odontoblast layer (data not shown).
The expression level of FAM20C in the odontoblasts and ameloblasts in the newborn mice ( Figures 5A-5G ) increased dramatically, when compared with the earlier stages. At this stage, FAM20C was observed in the newly formed dentin and enamel matrix ( Figure 5F) ; it was clearly detected in the dentin matrix in the 1-week-old mice ( Figure 6D ). The tendency of increasingly intense FAM20C signals in the molar continued until 3 weeks after birth (data not shown). After postnatal 3 weeks, the expression of FAM20C in the first lower molar decreased with age ( Figures 6E and 6G) , and nearly faded away at 7 weeks ( Figures 7E and 7F) . However, the expression in the incisor and PDL fibroblasts remained at consistently high levels after postnatal 3 weeks ( Figures 6E, 7C , 7E, and 7G).
FAM20C was also detected at a high level in the cerebrum cortex and cranial nerve ganglia in the E15.5 and E16.5 embryos (data not shown) and in the newborn mice ( Figure 5A ). These observations provide clues into the intracranial calcification phenotype in patients with lethal osteosclerotic bone dysplasia caused by mutations in the FAM20C gene.
In the negative control experiments of the ISH analyses, the sense probe did not detect appreciable signals ( Figure 6F ). In the first set of IHC control experiments, in which the anti-FAM20C antibody was replaced by normal rabbit IgG, no immunostaining signals were observed (data not shown). In the second set of control experiments, in which the anti-FAM20C antibody was preincubated with the immunizing oligopeptide, the immunostaining signals were negligible ( Figure 6H ).
Discussion
The biomineralization processes in the skeletal and dental tissues, involving complex interplays between the promoters and inhibitors of mineralization, must be tightly regulated and restricted to sites where mineral formation is required for proper tissue function. Although the molecules that initiate and promote biomineralization are essential for the formation of healthy hard tissues, the inhibitory factors are also critical for correctly constructing these tissues and, more importantly, for preventing the unwanted ectopic mineralization of soft tissues. A number of molecules have been identified as promoters for the mineralization of bone and tooth, but relatively little is known about the molecules preventing this process from occurring too rapidly or taking place in unwanted locations (Giachelli 2005) . The delicate interplay involved in maintaining the balance between the promoters and inhibitors of mineralization is well demonstrated by the inherited lethal osteosclerotic bone dysplasia caused by mutations in the FAM20C gene (Simpson et al. 2007 ). The main characteristic of lethal osteosclerotic bone dysplasia is overcalcification in both the skeleton and the non-mineralized tissues. The association of mutations in the FAM20C with lethal osteosclerotic bone dysplasia indicates that this protein may act as an important inhibitor for mineralization during osteogenesis.
Premature mineralization may have severe consequences in bone and teeth (Bi et al. 2001) . Before biomineralization, the cells secreting ECM need time to regulate the order of the collagen fibers and modify the composition of the premature ECM. In this study, FAM20C mRNA was detected in the osteoblasts, odontoblasts, and ameloblasts. FAM20C protein was also detected in these cells and in the matrices of bone, dentin, and enamel. The presence of FAM20C in the ECM of these tissues, plus the observation that the majority of FAM20C was secreted into cell culture medium during the transfection experiments, confirmed the previous speculation that FAM20C is a secretory protein.
After postnatal 7 weeks, the expression of FAM20C nearly faded away in the odontoblasts of the first lower molar, but remained at relatively high levels in the ameloblasts and odontoblasts of the incisors producing new matrices. This finding suggested that FAM20C is necessary in the cells actively forming dental tissues. These observations support the hypothesis that FAM20C secreted into the ECM plays an important role in mineralization by preventing the precursors of these hard tissues (predentin, osteoid, and enameloid) from being mineralized prematurely; thus, these cells are protected from the destructive effects of a too-rapid mineralization, and the ECM is guaranteed the time needed to refine its structure.
Although the FAM20C mRNA signal disappeared in the osteocytes upon maturation (i.e., the cells completely embedded in the matrix), its protein remained in these cells for a long time. Taking into consideration the presence of the osteocytes in a highly mineralizing ' Figure 3 environment and the importance of these cells for the health of the bone, it is tempting to believe that FAM20C in the mature osteocytes may function as one of the key factors keeping the cells "alive" (i.e., keeping them from being calcified). A high level of FAM20C was also detected in the cerebrum cortex and cranial nerve ganglia in newborn mice; these two tissues are calcified in lethal osteosclerotic bone dysplasia disease (Rejjal 1998) . All these observations seem to support the belief that FAM20C is an important inhibitor of calcification in the skeleton and in ectopic sites.
The biological roles of FAM20C may not be restricted to being only a biomineralization inhibitor. In this study, FAM20C was detected in the dental epithelium at the early cap stage of E14.5 before the differentiation of these cells into ameloblast lineage. The in vitro gain and loss of function indicated that the over expression of FAM20C accelerates the differentiation of cells into odontoblasts and promotes mineralized nodule formation; furthermore, silencing FAM20C by RNA interference inhibits odontoblast differentiation and mineralization ). Kirsch reported that only the maturing chondrocytes release matrix vesicles that initiate the mineralization process (Kirsch et al. 1997) . In this study, FAM20C was detected not only in the maturing chondrocytes but also in the articular chondrocytes and proliferative chondrocytes. These observations suggest that FAM20C might also be involved in chondrogenesis and in the early stages of bone and tooth development.
In the PDL, a discrepancy in signal intensity between the IHC and ISH results was observed, with a high level of FAM20C mRNA and a relatively low level of its protein in the PDL fibroblasts. Such a "mismatch" between FAM20C mRNA and its protein level was likely due to the differences in the degradation rate between the mRNA and its protein in these cells. The PDL in young rodents, which have a relatively high metabolic rate, may degrade the FAM20C protein very rapidly; thus, IHC did not reveal a great amount of FAM20C protein, whereas ISH demonstrated a high level of expression for this molecule at the transcriptional level. Based on the belief that Figure 6 FAM20C expression in the teeth of 1-and 5-week-old mice. (A) ISH staining on a sagittal section of the first lower molar from a 1-weekold mouse. (B) Higher magnification of the boxed area in A shows the presence of FAM20C mRNA in the odontoblasts (black arrow), ameloblasts (arrowhead), and osteoblasts (white arrow). (C) IHC staining on a serial section of A. (D) Higher magnification of the boxed area in C; FAM20C protein was found in the odontoblasts (black arrow), ameloblasts (black arrowhead), osteoblasts (white arrow), and osteocytes (white arrowhead). (E) ISH staining (using antisense probe) on a sagittal section of the first lower molar from a 5-week-old mouse, indicating FAM20C mRNA in the odontoblasts (arrow) and fibroblasts of periodontal ligament (PDL; arrowhead). (F) ISH staining using sense RNA probe (negative control) on a section serial to E was negative. (G) IHC staining on a sagittal section of the first lower molar from a 5-week-old mouse; FAM20C protein was present in the odontoblasts (arrow) and osteocytes (arrowhead). (H) Negative control of IHC staining. In this experiment, the anti-FAM20C antibody was first incubated with the immunizing oligopeptide and then applied to a section serial to G. The IHC control showed negative staining. Note that the immunostaining signals were negligible. Bars: A,C,E-H 5 200 mm; B,D 5 50 mm. this protein may be a mineralization inhibitor and the fact that the PDL is "sandwiched" between two mineralized tissues, cementum and alveolar bone, it is tempting to think that this protein may be important in preventing PDL from being mineralized. It might provide valuable information about the role of FAM20C as we examine whether the inactivating mutations in the FAM20C gene, as in the case of lethal osteosclerotic bone dysplasia, may result in tooth ankylosis in these patients (Wescott et al. 2007) or in animal models.
FAM20C has been speculated to be a secretory protein based on sequence analysis (Nalbant et al. 2005) . In this study, the detection of FAM20C in the ECM of hard tissues, along with the observation that the majority of the FAM20C synthesized by the HEK293-EBNA cells was secreted into the culture medium, provided direct evidence that FAM20C is an ECM protein.
In summary, we performed IHC and ISH to investigate the expression profiles of FAM20C in bone and tooth from E13.5 to 8 weeks after birth. FAM20C protein Figure 7 FAM20C expression in the teeth of 5-and 7-week-old mice. (A) ISH staining on a sagittal section of the first lower molar from a 5-weekold mouse; FAM20C mRNA was visible in the odontoblasts (black arrow), cementoblasts (arrowheads), and fibroblasts of PDL (white arrow). (B) IHC staining on a section serial to A; FAM20C protein was found in the odontoblasts (arrow) and cementoblasts (arrowheads). (C) ISH staining of a cross-section at the middle of the incisor root from a 5-week-old mouse; there was FAM20C mRNA in the odontoblasts (arrow) and ameloblasts (arrowhead). (D) IHC staining on a section serial to C showed FAM20C protein in the odontoblasts (arrow) and ameloblasts (arrowhead). (E) ISH staining on a sagittal section of the first lower molar from a 7-week-old mouse revealed FAM20C mRNA in PDL fibroblasts (white arrow) but not in odontoblasts (black arrows). (F) IHC staining on a sagittal section of the first lower molar from a 7-week-old mouse; FAM20C protein had disappeared in the majority of the odontoblasts (black arrows), whereas a small portion of the odontoblasts (white arrowheads) beneath the tooth cusp tips remained positive for this protein. (G) ISH staining on a cross-section in the middle of the incisor root from a 7-week-old mouse; FAM20C mRNA was found in the odontoblasts (black arrow), ameloblasts (black arrowhead), and PDL fibroblasts (white arrow). (H) IHC staining on a section serial to G showing FAM20C protein in the odontoblasts (black arrow), ameloblasts (black arrowhead), and PDL matrix (white arrow). Bars: A,B 5 50 mm; C-H 5 200 mm.
was detected in the odontoblasts, ameloblasts, cementoblasts, and osteoblasts and in the matrices of dentin, enamel, and bone. FAM20C was also detected in the early-stage tooth germs and chondrogenic cells in the long bone. These observations suggest that FAM20C may be involved in the differentiation, as well as in the control, of mineralization during bone and tooth development. However, further investigation, especially the gain and loss of function in vivo, is warranted to delineate the exact roles of FAM20C in osteogenesis and odontogenesis.
